Merck
CN
所有图片(1)

文件

1457403

USP

萘普生 钠

United States Pharmacopeia (USP) Reference Standard

登录查看公司和协议定价
所有图片(1)
别名:
(S)-6-甲氧基-α-甲基-2-萘乙酸 钠盐
经验公式（希尔记法）:
C14H13NaO3
CAS号:
26159-34-2
分子量:
252.24
MDL编号:
MFCD00058507
PubChem化学物质编号:
329750531
NACRES:
NA.24

等级

pharmaceutical primary standard

API family

naproxen

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

格式

neat

SMILES string

[Na+].COc1ccc2cc(ccc2c1)[C@H](C)C([O-])=O

InChI

1S/C14H14O3.Na/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;/h3-9H,1-2H3,(H,15,16);/q;+1/p-1/t9-;/m0./s1

InChI key

CDBRNDSHEYLDJV-FVGYRXGTSA-M

Gene Information

human ... PTGS1(5742) , PTGS2(5743)

正在寻找类似产品? Visit 产品对比指南

相关类别

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Naproxen sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

生化/生理作用

环加氧酶（前列腺素 H 合成酶 1 和 2）抑制剂。

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

相关产品

产品编号
说明
价格

PHR1040

萘普生, Pharmaceutical Secondary Standard; Certified Reference Material

1457301

萘普生, United States Pharmacopeia (USP) Reference Standard

N0250000

萘普生, European Pharmacopoeia (EP) Reference Standard

Y0000399

萘普生, European Pharmacopoeia (EP) Reference Standard

Y0000631

萘普生杂质L, European Pharmacopoeia (EP) Reference Standard

1457312

6-甲氧基-2-萘甲酸, United States Pharmacopeia (USP) Reference Standard

1457425

6′-甲氧基-2′-萘乙酮, United States Pharmacopeia (USP) Reference Standard

08129

6-甲氧基-2-萘酚, pharmaceutical impurity standard

79584

2-Ethyl-6-methoxynaphthalene, pharmaceutical impurity standard

80713

(1RS)-1-(6-Methoxynaphthalen-2-yl)ethanol, pharmaceutical impurity standard

82170

(R)-(-)-6-甲氧基-α-甲基-2-萘乙酸, pharmaceutical impurity standard

07506

(S)-Naproxen ethyl ester, pharmaceutical impurity standard

80822

(S)-Naproxen methyl ester, pharmaceutical impurity standard

80816

(2S)-2-(5-Chloro-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

80821

(2S)-2-(5-Iodo-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

80818

(2S)-2-(5-Bromo-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

07503

2-溴-6-甲氧基萘, pharmaceutical impurity standard

07499

2-甲氧基萘, pharmaceutical impurity standard

07547

6-甲氧基-2-萘甲酸, pharmaceutical impurity standard

BP435

萘普生, British Pharmacopoeia (BP) Reference Standard

1457436

(R)-(-)-6-甲氧基-α-甲基-2-萘乙酸, United States Pharmacopeia (USP) Reference Standard

PHR2254

萘普生, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2256

Naproxen 1,3-Butylene Glycol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2219

Naproxen 1,2 Propylene Glycol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2248

Naproxen 2,3-Butylene Glycol Ester, pharmaceutical secondary standard

PHR2257

萘普生异丙酯, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2524

萘普生杂质N, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2525

萘普生杂质M, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2527

Naproxen Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2526

6-甲氧基-2-萘酚, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2520

Naproxen Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2519

Naproxen Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2518

(R)-(-)-6-甲氧基-α-甲基-2-萘乙酸, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2523

萘普生相关化合物L, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2530

rac-Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2517

萘普生相关化合物K, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2521

萘普生杂质A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2522

萘普生杂质I, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2528

萘普生杂质F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2529

萘普生杂质E, Pharmaceutical Secondary Standard; Certified Reference Material

象形图

Exclamation markHealth hazard
GHS07,GHS08

警示用语：

Danger

危险声明

H302 - H360

危险分类

Acute Tox. 4 Oral - Repr. 1A

储存分类代码

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。

  • 如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。

  • 如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Arın Gül Dal et al.
Journal of analytical methods in chemistry, 2014, 352698-352698 (2014-10-09)
Simple and rapid capillary zone electrophoretic method was developed and validated in this study for the determination of piroxicam in tablets. The separation of piroxicam was conducted in a fused-silica capillary by using 10 mM borate buffer (pH 9.0) containing 10%
Matteo Morotti et al.
European journal of obstetrics, gynecology, and reproductive biology, 179, 63-68 (2014-06-27)
Evaluate patient satisfaction at 6-month treatment in women with symptomatic rectovaginal endometriosis and migraine without aura with (progestogen-only contraceptive pill, POP versus sequential combined oral contraceptives, COC) STUDY DESIGN: A patient preference trial including 144 women (82 in the group
Jason A Miranda et al.
PloS one, 9(8), e106108-e106108 (2014-08-27)
Sensory processing in the spinal cord during disease states can reveal mechanisms for novel treatments, yet very little is known about pain processing at this level in the most commonly used animal models of articular pain. Here we report a
Tarjinder Sahota et al.
Toxicology and applied pharmacology, 278(3), 209-219 (2014-03-29)
The assessment of safety in traditional toxicology protocols relies on evidence arising from observed adverse events (AEs) in animals and on establishing their correlation with different measures of drug exposure (e.g., Cmax and AUC). Such correlations, however, ignore the role
Jennifer Y Xie et al.
Pain, 155(8), 1659-1666 (2014-05-28)
Preclinical assessment of pain has increasingly explored operant methods that may allow behavioral assessment of ongoing pain. In animals with incisional injury, peripheral nerve block produces conditioned place preference (CPP) and activates the mesolimbic dopaminergic reward pathway. We hypothesized that
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门